- Home
- IBTA vs CERT Comparison
IBTA vs CERT Comparison
Compare IBTA & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBTA | CERT |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 605.8M | 1.3B |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IBTA | CERT |
|---|---|---|
| Price | $22.17 | $8.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $37.38 | $14.50 |
| AVG Volume (30 Days) | 506.5K | ★ 2.0M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 395.09 | N/A |
| EPS | ★ 2.40 | 0.07 |
| Revenue | $352,243,000.00 | ★ $415,551,000.00 |
| Revenue This Year | N/A | $10.82 |
| Revenue Next Year | N/A | $6.77 |
| P/E Ratio | ★ $9.20 | $130.24 |
| Revenue Growth | N/A | ★ 11.47 |
| 52 Week Low | $22.00 | $8.03 |
| 52 Week High | $76.84 | $15.69 |
Technical Indicators
Market Signals| Indicator | IBTA | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 34.42 | 40.92 |
| Support Level | $22.19 | $8.95 |
| Resistance Level | $24.40 | $9.42 |
| Average True Range (ATR) | 0.87 | 0.39 |
| MACD | 0.07 | 0.13 |
| Stochastic Oscillator | 3.54 | 46.91 |
Price Performance
Historical ComparisonAbout IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.